



- SÚKL – Státní ústav pro kontrolu léčiv
- TNF α – Tumor nekrotizující faktor α

LITERATURA

1. Abrams EM, Khan DA. Diagnosing and managing drug allergy. *CMAJ*, 2018; 190(17): E532–E538.
2. Pichler WJ, Hausmann O. Classification of Drug Hypersensitivity into Allergic, p-i, and Pseudo-Allergic Forms. *Int Arch Allergy Immunol* 2016; 171: 166–179.
3. Montanez MI, Mayorga G, Bogas G, et al. Epidemiology, mechanisms, and diagnosis of drug-induced anaphylaxis. *Front Immunol* 2017; 9: 614.
4. Nemšovská J. Liekové hypersenzitivne reakcie: klasifikácia a patogenéza (1.časť). *Čes-slov Derm* 2019; 94(3): 99–106.
5. Ardern-Jones M, Friedmann PS. Skin manifestations of drug allergy. *Br J Clin Pharmacol* 2010; 71(5): 672–683.
6. Kováčová S. DIHS – liekmi indukovaný hypersenzitívny syndróm. *Dermatol Prax* 2014; 8(2): 40–64.
7. Nemšovská J. Liekové hypersenzitivne reakcie: diagnostika a liečba (2.časť). *Čes-slov Derm* 2019; 94 (5): 192–202.
8. Mayorga C, Celik G, Rouzaire P. et al. In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper. *Allergy* 2016; 71: 1103–1134.
9. Crisafulli G, Franceschini F, Caimmi S, Bottau P, Liotti L, Saretta F, Bernardini R, Cardinale F, Mori F, Caffarelli C. Mild cutaneous reactions to drugs. *Acta Biomed* 2019; 90(Suppl. 3): 36–43.
10. Barbaud A. Skin testing and patch testing in non-IgE-mediated drug allergy. *Curr Allergy Astma Rep* 2014; 442(14): 1–8.
11. Friedmann P. S., Ardern-Jones M. Patch testing in drug allergy. *Curr Opin Allergy Clin Immunol* 2010; 10: 291–296.
12. Scherer K., Brockow K., Aberer W. Desensitization in delayed drug hypersensitivity reactions – an EAACI position paper of Drug Allergy Interest Group. *Allergy* 2013; 68(7): 844–852.